Q-omics provides the consensus-scored ANKHD1 profile across patient tissues and cancer cell-line models. ANKHD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ANKHD1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ANKHD1 protein abundance shows 20,436 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where ANKHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKHD1 survival associations across molecular data types. ANKHD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKHD1 RNA expression–survival associations across cancer types. High ANKHD1 expression shows unfavorable associations in ACC, KICH, UVM and COAD, but favorable associations in SKCM and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ANKHD1 RNA expression.
This table summarizes ANKHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ANKHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKHD1 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, HNSC, CHOL and KIRP. The KIRC box plot shows higher ANKHD1 RNA expression in tumor versus normal tissue (log2 FC = +0.669, t-test p < 0.001).
This table shows molecular features associated with ANKHD1 in patient tissues and cancer cell lines. In patient samples, ANKHD1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
